X0206 3 2014-03-19 0 0001517022 Akebia Therapeutics, Inc. AKBA 0001602395 Shalwitz Robert C/O AKEBIA THERAPEUTICS, INC. 245 FIRST STREET, SUITE 1100 CAMBRIDGE MA 02142 0 1 0 0 Chief Medical Officer Common Stock 20000 D Common Stock 214980 D Series A Convertible Preferred Stock Common Stock 4248 D Series B Convertible Preferred Stock Common Stock 3623 D Series C Convertible Preferred Stock Common Stock 4689 D Series A Convertible Preferred Stock Common Stock 17016 I By Fred Shalwitz Trust Stock Option (Right to Buy) 0.86 2018-06-01 Common Stock 66550 D Stock Option (Right to Buy) 0.86 2020-07-28 Common Stock 30333 D Stock Option (Right to Buy) 0.86 2022-01-12 Common Stock 18675 D 17,000 of the shares represents fully-vested restricted stock issued pursuant to the August 31,2009 restricted stock agreement. 60,542 of the shares represents fully-vested restricted stock issued pursuant to the June 15, 2011 restricted stock agreements. 10,266 of the shares represents unvested shares issued pursuant to the June 15, 2011 restricted stock agreement, which will vest in equal monthly installments through April 6, 2015. 127,172 of the shares represents unvested shares issued pursuant to the December 23, 2013 restricted stock agreement, the shares will vest as follows: 25% vest on December 23, 2014, with the remainder of the shares vesting in equal quarterly installments over the following three years through December 23, 2017. The Series A Convertible Preferred Stock are convertible into Common Stock on a one for five basis (as adjusted for the 1.75-for-1 stock split effected on March 6, 2014), at any time at the holder's election, and automatically upon the closing of the Issuer's initial public offering, and have no expiration date., The Series B Convertible Preferred Stock are convertible into Common Stock on a one for 1.75 basis (as adjusted for the 1.75-for-1 stock split effected on March 6, 2014), at any time at the holder's election, and automatically upon the closing of the Issuer's initial public offering, and have no expiration date. Represents 4,689 shares of Series C Preferred Stock (the "Preferred Stock"). The Series C Preferred Stock has no expiration date and is convertible at any time, at the holder's election. Upon the closing of the Issuer's initial public offering, the Series C Preferred Stock will automatically convert into shares of the Issuer's Common Stock, with a conversion ratio equal to the Series C Accrued Value (the original issuance price of $14.00 adjusted for the 1.75 stock split, plus accrued but unpaid cash dividends) divided by the Applicable Conversion Price of $14.00, as provided in the Issuer's Eighth Amended and Restated Certificate of Incorporation. The shares shown reflect an anticipated conversion date of March 25, 2014. This option is fully-vested and exercisable. 27,632 of the shares are fully-vested and exercisable as of March 19, 2014. The remaining 2,701 shares will vest in equal monthly installments through July 28, 2014. 10,451 of the shares are fully-vested and exercisable as of March 19, 2014. The remaining 8,225 shares will vest in equal monthly installments through December 23, 2015. Exhibit List Exhibit 24 - Limited Power of Attorney /s/ Nicole R. Hadas, attorney-in-fact 2014-03-19